-DOCSTART- -X- O
Shigella -X- _ O
spp. -X- _ O
are -X- _ O
pathogenic -X- _ O
bacteria -X- _ O
that -X- _ O
cause -X- _ O
bacillary -X- _ O
dysentery -X- _ O
in -X- _ O
humans -X- _ O
by -X- _ O
invading -X- _ O
the -X- _ O
colonic -X- _ O
and -X- _ O
rectal -X- _ O
mucosa -X- _ O
where -X- _ O
they -X- _ O
induce -X- _ O
dramatic -X- _ O
inflammation. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
analyzed -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
the -X- _ O
soluble -X- _ O
PRR -X- _ O
Pentraxin -X- _ O
3 -X- _ O
( -X- _ O
PTX3 -X- _ O
) -X- _ O
, -X- _ O
a -X- _ O
key -X- _ O
component -X- _ O
of -X- _ O
the -X- _ O
humoral -X- _ O
arm -X- _ O
of -X- _ O
innate -X- _ O
immunity. -X- _ O
Mice -X- _ B-Patient
that -X- _ I-Patient
had -X- _ I-Patient
been -X- _ I-Patient
intranasally -X- _ I-Patient
infected -X- _ I-Patient
with -X- _ I-Patient
S. -X- _ I-Patient
flexneri -X- _ I-Patient
were -X- _ O
rescued -X- _ O
from -X- _ O
death -X- _ O
by -X- _ O
treatment -X- _ O
with -X- _ O
recombinant -X- _ B-Intervention
PTX3. -X- _ I-Intervention
In -X- _ O
vitro -X- _ O
PTX3 -X- _ O
exerts -X- _ O
the -X- _ O
antibacterial -X- _ O
activity -X- _ O
against -X- _ O
Shigella -X- _ B-Outcome
, -X- _ I-Outcome
impairing -X- _ I-Outcome
epithelial -X- _ I-Outcome
cell -X- _ I-Outcome
invasion -X- _ I-Outcome
and -X- _ I-Outcome
contributing -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
bactericidal -X- _ I-Outcome
activity -X- _ I-Outcome
of -X- _ I-Outcome
serum. -X- _ I-Outcome
PTX3 -X- _ O
is -X- _ O
produced -X- _ O
upon -X- _ O
LPS-TLR4 -X- _ O
stimulation -X- _ O
in -X- _ O
accordance -X- _ O
with -X- _ O
the -X- _ O
lipid -X- _ O
A -X- _ O
structure -X- _ O
of -X- _ O
Shigella. -X- _ O
In -X- _ O
the -X- _ O
plasma -X- _ O
of -X- _ O
infected -X- _ O
patients -X- _ O
, -X- _ O
the -X- _ O
level -X- _ O
of -X- _ O
PTX3 -X- _ O
amount -X- _ O
only -X- _ O
correlates -X- _ O
strongly -X- _ O
with -X- _ O
symptom -X- _ O
severity. -X- _ O
These -X- _ O
results -X- _ O
signal -X- _ O
PTX3 -X- _ B-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
novel -X- _ I-Outcome
player -X- _ I-Outcome
in -X- _ I-Outcome
Shigella -X- _ I-Outcome
pathogenesis -X- _ I-Outcome
and -X- _ I-Outcome
its -X- _ I-Outcome
potential -X- _ I-Outcome
role -X- _ I-Outcome
in -X- _ I-Outcome
fighting -X- _ I-Outcome
shigellosis. -X- _ I-Outcome
Finally -X- _ O
, -X- _ O
we -X- _ O
suggest -X- _ O
that -X- _ O
the -X- _ O
plasma -X- _ B-Outcome
level -X- _ I-Outcome
of -X- _ I-Outcome
PTX3 -X- _ I-Outcome
in -X- _ I-Outcome
shigellosis -X- _ I-Outcome
patients -X- _ I-Outcome
could -X- _ I-Outcome
act -X- _ I-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
biomarker -X- _ I-Outcome
for -X- _ I-Outcome
infection -X- _ I-Outcome
severity -X- _ I-Outcome
. -X- _ O

